Labels and claims

Cosmetic Label Requirements: FDA & MoCRA Checklist for 2026

By ProductGuard. Published by M Huzaifa. October 19, 2026.

A cosmetic label can look finished and still have problems hiding in plain sight. The ingredient list may be formatted incorrectly, the net quantity may be placed poorly, or the packaging may say one thing while the product page makes a much stronger claim.

If you are holding a carton, a jar, or a print proof, use this as a pass over the major areas before launch, or before you change packaging on something already for sale. The notes below are for a product sold in the United States. Where a detail depends on the specific item, the link goes to FDA’s page or the regulation.

Cosmetic label checklist at a glance

Walk the proof in this order. The later sections say what “done” looks like for each line, and where brands usually stop too early.

Start with the principal display panel

The principal display panel is the part of the label a shopper is most likely to see under ordinary retail display. On a folding carton, that is usually the front. FDA’s Cosmetics Labeling Guide describes it that way. The placement rule is 21 CFR 701.10.

Picture a fictional face cream, Northline Daily, in a carton. This is not a real product. The front is mostly the word NORTHLINE, a thin line that says “for tired skin,” and “1.7 oz” set in the gold band beside the logo, near the top. The jar inside has the brand name and nothing else. The design looks finished. It would still come back with marks.

The front has to say what the product is. That identity can be the common or usual name, a descriptive name, a fanciful name when the nature of the product is already obvious, or an illustration. It has to appear in bold type, in a size reasonably related to the most prominent printed matter, in lines generally parallel to the base. “For tired skin” is a mood. It does not tell someone this is a face cream. “Northline Daily Face Cream,” or the words “Face cream” under the brand, does that job. The rule is 21 CFR 701.11.

The net quantity belongs on that same front panel, as its own statement, with space around it, inside the bottom 30 percent of the panel, generally parallel to the base. The bottom-area placement is waived when the panel is 5 square inches or less. A cream, or anything solid, semisolid, or viscous, is declared by weight, and the statement uses “net wt.” A liquid is declared by fluid measure, such as “fl. oz.” Copying the cream template onto a watery serum, and printing “1.7 oz” with no “fl,” is a common artwork miss. You may add metric units. They do not replace the U.S. customary statement. At a pound or a pint and above, the way the larger units are shown gets more specific, so check 21 CFR 701.13 before you lock a big size. FDA’s short version is the summary of cosmetics labeling requirements.

If the cream is sold in a carton, the carton is the outer package and it carries the principal display panel. If that carton is discarded, the inner container still has its own required labeling, including the product name, quantity, business information, and any applicable warnings or directions.

Ingredient declaration

Open the formula the lab is actually filling, not the deck from the first sample. Then read the list on the carton, the jar, and the product page against that formula. This is the check that catches a quiet substitution: a different preservative, a fragrance someone thought had been dropped, an ingredient the website still features because it was in version two.

For a cosmetic sold at retail for personal care, the ingredients go on an information panel of the outer package. They can go on a firmly attached tag, tape, or card when the container is small or decorative. They are declared in descending order of predominance. Ingredients present at 1 percent or less may be listed in any order after the ingredients above 1 percent. Color additives may be listed in any order after the ingredients that are not colors. The type is generally at least 1/16 inch high. When the surface available for labeling is under 12 square inches, the minimum is 1/32 inch. The list still has to be readable at purchase. A hairline list reversed out of a photograph fails that test even when the names are right. The details are in 21 CFR 701.3 and the labeling guide.

Use the name the labeling rule points to, not the name in the ad. A front callout can say vitamin C. The declaration should use the ingredient name, such as ascorbic acid, in its place in the order. Manufacturers usually send this list in the names used for cosmetic labeling, often the INCI name. Paste from that list. A shortened column that drops the preservative system is not a layout choice. It is a different list.

Fragrance and flavor may be declared as “fragrance” and “flavor.” If one compound does both jobs, the words are “flavor and fragrance.” The components may also be named individually. A product page that lists three essential oils, while the carton says only “fragrance,” is a consistency problem even when each version can be lawful on its own. MoCRA directs FDA to identify fragrance allergens by regulation and require them on the label. FDA has not finished that regulation. Until it does, an EU-style allergen list on a U.S. carton is a choice, not a completed FDA labeling rule. If you sell in both places, build the two lists on purpose.

Color is where shade lines get sloppy. The colors printed for a single finished shade should be the colors in that shade. The regulation allows a “may contain” approach for color additives in certain assortments and shade lines. That phrase is not a way to paper over uncertainty about one formula. If the website uses one ingredient block for every shade, check it against each SKU.

Products used only by professionals, and not also sold to consumers for use at home, can fall outside the ingredient-declaration requirement. The moment that backbar jar is also on your site, treat the declaration as in scope.

Business and contact information

Two lines get collapsed into “put our address on it.” They do different jobs.

The label has to name the manufacturer, packer, or distributor and give a place of business: street, city, state, and ZIP code. The street may be omitted only if it is already shown in a current city directory or telephone directory. A website is not that directory. If the name on the label is not the manufacturer, qualify it with “Manufactured for,” “Distributed by,” or other words that state the real relationship. For a corporation, the name is the actual corporate name. A brand lockup is not automatically that name. This is 21 CFR 701.12.

Separately, the label has to give people a way to reach the responsible person about a problem: a domestic address, a domestic phone number, or electronic contact information, which may include a website. That requirement is section 609(a) of the FD&C Act, added by MoCRA. FDA defines the responsible person as the manufacturer, packer, or distributor whose name appears on the label. On a proof, look for a foreign address with no domestic contact path, or a beautiful site with nowhere to report a reaction. FDA’s overview is the MoCRA page.

Warnings and directions

There is no single warning paragraph that belongs on every cream. A warning is required when one is necessary or appropriate to prevent a health hazard associated with the product, and some products have mandatory text of their own. A cosmetic whose safety has not been adequately substantiated has to bear this statement on the principal display panel: “Warning - The safety of this product has not been determined.” Self-pressurized containers have their own warning. A foaming detergent bath product that is not clearly limited to adults needs a caution and adequate directions for safe use. Those live in 21 CFR 740. Read the section that matches the product in your hand. Keep a warning a safety review already gave you. Do not add one you do not need just to make the back panel look official.

Directions follow the product. A drug-style directions panel is not the default for a cosmetic. Some products still need directions for safe use, and a leave-on oil and a rinse-off scrub are not the same instruction. If the way someone might use the product has a consequence they would not expect, a blank back panel is a review item.

Required statements have to be in English. If the label also uses another language, those required statements have to appear in that language as well.

Claims are where a cosmetic can change categories

“Moisturizes dry-looking skin” sits in the cosmetic definition FDA uses: cleansing, beautifying, promoting attractiveness, or altering the appearance.

“Treats eczema” does not. Drugs, under the statute FDA applies, include articles intended to diagnose, cure, mitigate, treat, or prevent disease, and articles intended to affect the structure or function of the body. A product can be both, the way an antidandruff shampoo cleanses and treats. FDA’s short explanation is “Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)”

Intended use is not the category you typed into Shopify. FDA says it can be shown by claims on labeling, in advertising, on the internet, or in other promotion; by what consumers are led to expect; and sometimes by an ingredient the public already understands as a drug, such as fluoride in toothpaste. Acne treatments, dandruff treatments, and skin protectants are drug categories in FDA’s industry explainer. A cleanser sold as an acne treatment has to meet both sets of rules. A face wash that only talks about cleansing does not pick up that obligation because acne products sit nearby.

Using a disease term deserves a closer look, but the full context and intended use matter. FDA does not publish a banned-word list, and it does not pre-approve cosmetic claims. Its cosmetics labeling claims page says claims have to be truthful and not misleading. “This is not a treatment for eczema” in a help article is a different presentation from a product named Eczema Relief Cream, with photos of a rash. Read the impression. Condition-oriented marketing is covered in when cosmetic marketing changes how a product is interpreted, and the category line is in cosmetic vs. drug claims.

Appearance claims have a boundary too. FDA’s page on wrinkle treatments and other anti-aging products says that making lines less noticeable by moisturizing can be cosmetic, and that removing wrinkles or increasing the skin’s production of collagen is a different intended use. If you meant the first sentence, do not let the second onto the carton because it sounds more serious. Sun protection is the same kind of fork: a moisturizer marketed with an SPF claim is a cosmetic and a drug.

A claim can stay inside cosmetic territory and still be one you cannot support. The Federal Trade Commission expects advertising claims to have a reasonable basis. Its Health Products Compliance Guidance is the business guide for health-related advertising. Proof language such as “clinically proven” is its own question, covered in what “clinically proven” is asking you to show.

The label is only one part of the review

A careful carton can sit next to a product page that undoes it. The package says “moisturizes dry-looking skin.” The Shopify title says “eczema cream.” The Amazon bullets promise relief. The FAQ answers “yes, it treats flare-ups.” A social ad uses a rash photo. The influencer brief asks the creator to talk about healing. The jar never said that. Customers experience the product across all of these surfaces, not just the package.

FDA treats claims on the internet and in advertising as part of how intended use is established. The FTC treats the advertising as advertising. ProductGuard reviews the label, the listing, and the marketing together for that reason. A label-only pass can miss the sentence that actually changes the product.

Your website is part of the picture

Review what the customer sees, in the order they see it.

The product title does more work than people budget for. A marketplace title, and the words a search result shows first, can carry a stronger implication than the paragraph underneath. If the name says “eczema” and the description says “daily moisture,” the name is the claim a shopper remembers.

The description and the bullets are where a rewrite tends to upgrade a cosmetic into a treatment. That includes a draft from a model, which will often copy the condition language already common in the category. Compare the output with the claim you are willing to print. That failure mode is spelled out in AI-generated product descriptions.

FAQs drift because they are written in the customer’s words, and the customer’s words are often a condition. Answering in those words can create the claim the label avoided.

A testimonial you chose to publish is your advertising. “Cleared my eczema in a week” on the product page is no longer a private review. The FTC’s Endorsement Guides are the reference for what that quote is doing. If a creator says it, the brief and the disclosure both matter. Disclosures are covered in FTC influencer disclosure basics.

Then open the Amazon listing, or whichever marketplace you use, including text baked into images. A deal graphic is still a claim. So is the paid ad, the organic caption, and the script you sent out. If the brief asks for a treatment result, the post is your claim, including when the carton stayed conservative.

A packaging change can leave the old story up

This shows up when the package is updated and the rest of the footprint is not. The lab changes a preservative. The new carton is correct. The product page, the Amazon listing, a retailer’s content module, and a pinned post still describe the old formula, the old size, or a claim you took off the front panel on purpose. Sometimes the ingredient list on the site is the one from a sample you did not approve.

Packaging, the store, and ads are often edited by different people on different days. Treat a packaging change as a reason to reread the whole path a customer can still find: carton, container, site, marketplace, FAQ, and anything still live. If you are earlier than that, and you are still building the first product, the sequence from formula through label is in how to launch a skincare brand.

MoCRA considerations

MoCRA, the Modernization of Cosmetics Regulation Act of 2022, expanded FDA’s authority over cosmetics. It did not create an approval program for claims, and it does not apply every new obligation the same way to every small company. Use FDA’s MoCRA page and the registration and listing page, not a screenshot from a slide deck.

The responsible person is the manufacturer, packer, or distributor whose name is on the label. That is the party tied to the product listing and to serious adverse event reports.

Facilities that manufacture or process cosmetics distributed in the United States generally register with FDA and renew every two years. The responsible person generally lists each marketed cosmetic, including the ingredients, and updates that listing annually. FDA is explicit that a facility registration number or a product listing number is not an approval, and that FDA does not issue a certificate to prove you registered or listed. A label that implies FDA approved the cosmetic is false or misleading. Registration is not a promotional tool, so “FDA registered” does not belong on the front as a seal.

Certain small businesses are exempt from facility registration, product listing, and the good manufacturing practice requirements MoCRA directs FDA to establish. That exemption does not cover products that regularly contact the mucus membrane of the eye, products that are injected, products intended for internal use, or products intended to alter appearance for more than 24 hours when removal by the consumer is not part of customary use. If you think you are exempt, use FDA’s materials for this product. The exemption FDA describes is about registration, listing, and GMP. It is not a pass on the label, on safety substantiation, or on serious adverse event reporting.

Safety substantiation is a record you can produce, not a badge for the carton. The responsible person has to ensure and maintain records supporting adequate substantiation of safety. FDA does not require one named test for every product, and MoCRA does not require animal testing. The data still has to come from scientifically robust methods. If safety has not been adequately substantiated, the labeling consequence is the warning in 21 CFR 740.10, quoted above.

A serious adverse event associated with use in the United States is reported to FDA within 15 business days, with a copy of the label. If more medical information arrives within a year of that report, it is due within 15 business days as well. FDA’s definition includes death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, a congenital anomaly or birth defect, an infection, or significant disfigurement, including serious and persistent rashes, second- or third-degree burns, significant hair loss, or a persistent or significant change in appearance other than what the product was intended to do. It also includes a medical or surgical intervention, based on reasonable medical judgment, that is needed to prevent one of those outcomes. A mild comment in a review is not automatically that report. A serious one is a clock, and the contact on the label has to reach a person who knows it.

Two related items are still unfinished rulemaking. Do not print them as if the text were final. FDA has not completed the regulation that will name which fragrance allergens must appear on the label. GMP for cosmetic facilities is a regulation FDA is required to write. What is public includes draft guidance. It is not a finished code you can treat as the only manufacturing checklist.

Five mistakes we repeatedly see when reviewing product information

These are common patterns ProductGuard is designed to look for, not statistics from customer audits.

The label and the website make different claims. The carton stays with appearance. The product page promises a treatment, or a change in structure such as increasing collagen. The second sentence is the one that can move the product.

The product name does more work than the description. The paragraph says “daily moisture.” The title says “eczema,” “acne,” or “treatment.” Shoppers read the name. So does an intended-use analysis.

Ingredient information differs between surfaces. The carton, the jar, the site, and the marketplace listing should be one list. A percentage on the front that the declaration and the batch record do not support belongs in the same pile.

Old ecommerce copy survives a packaging update. The new dieline is approved. The URL that still ranks describes the previous size, scent, or claim.

Cosmetic language drifts toward treatment language. It often happens one edit at a time: a FAQ answer, a creator brief, an image overlay, a bullet rewritten to match a search. None of those edits reopened the label.

Before you print or publish

Questions that come up with the proof in hand

Does the ingredient list have to be on the front?

No. For a retail cosmetic it belongs on an information panel, readable at purchase, or on a firmly affixed tag, tape, or card in the situations the regulation allows. The front still needs the identity of the product and the net quantity.

Are milliliters alone enough?

No. The U.S. statement uses the customary system: fluid measure for a liquid, weight for a solid, semisolid, or viscous product. You may also state metric units. Metric does not replace that statement.

Does an FDA listing mean the claims are fine?

No. Facility registration and product listing are not an approval, and FDA does not issue a certificate that says otherwise. A listing number does not review the product page.

Can the carton stay careful if the Amazon page is stronger?

The page is part of how the product is presented. A disease claim or a structure-or-function claim on the listing can change the intended-use picture even when the carton is restrained. Review them as one story.

Do I have to list every fragrance ingredient?

Current U.S. labeling allows “fragrance,” “flavor,” or “flavor and fragrance,” and it also allows the components to be named. FDA has not finished the rule that will say which fragrance allergens must be identified. An EU allergen list is not that unfinished rule.

Related guides